Asset Details
Do you wish to reserve the book?
Involvement of endogenous CCK and CCK1 receptors in colonic motor function
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Involvement of endogenous CCK and CCK1 receptors in colonic motor function
Do you wish to request the book?
Involvement of endogenous CCK and CCK1 receptors in colonic motor function
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Involvement of endogenous CCK and CCK1 receptors in colonic motor function
2004
Overview
Cholecystokinin (CCK) is a brain‐gut peptide; it functions both as a neuropeptide and as a gut hormone. Although the pancreas and the gallbladder were long thought to be the principal peripheral targets of CCK, CCK receptors are found throughout the gut. It is likely that CCK has a physiological role not only in the stimulation of pancreatic and biliary secretions but also in the regulation of gastrointestinal motility. The motor effects of CCK include postprandial inhibition of gastric emptying and inhibition of colonic transit. It is now evident that at least two different receptors, CCK1 and CCK2 (formerly CCK‐A and CCK‐B, respectively), mediate the actions of CCK. Both localization and functional studies suggest that the motor effects of CCK are mediated by CCK1 receptors in humans. Since CCK is involved in sensory and motor responses to distension in the intestinal tract, it may contribute to the symptoms of constipation, bloating and abdominal pain that are often characteristic of functional gastrointestinal disorders in general and irritable bowel syndrome (IBS), in particular. CCK1 receptor antagonists are therefore currently under development for the treatment of constipation‐predominant IBS. Clinical studies suggest that CCK1 receptor antagonists are effective facilitators of gastric emptying and inhibitors of gallbladder contraction and can accelerate colonic transit time in healthy volunteers and patients with IBS. These drugs are therefore potentially of great value in the treatment of motility disorders such as constipation and constipation‐predominant IBS. British Journal of Pharmacology (2004) 141, 1275–1284. doi:10.1038/sj.bjp.0705769
Publisher
Blackwell Publishing Ltd,Nature Publishing
Subject
/ Biological and medical sciences
/ Cholecystokinin - antagonists & inhibitors
/ Cholecystokinin - physiology
/ colon
/ Gastrointestinal Motility - drug effects
/ Gastrointestinal Motility - physiology
/ Humans
/ Pharmacology. Drug treatments
/ Receptor, Cholecystokinin A - antagonists & inhibitors
/ Receptor, Cholecystokinin A - genetics
/ Receptor, Cholecystokinin A - physiology
/ Reviews
